805 related articles for article (PubMed ID: 22065872)
21. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
23. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
24. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
[TBL] [Abstract][Full Text] [Related]
25. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
26. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Binns DS; Pirzkall A; Yu W; Callahan J; Mileshkin L; Conti P; Scott AM; Macfarlane D; Fine BM; Hicks RJ;
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):642-50. PubMed ID: 21207024
[TBL] [Abstract][Full Text] [Related]
27. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
[TBL] [Abstract][Full Text] [Related]
31. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Benz MR; Herrmann K; Walter F; Garon EB; Reckamp KL; Figlin R; Phelps ME; Weber WA; Czernin J; Allen-Auerbach MS
J Nucl Med; 2011 Nov; 52(11):1684-1689. PubMed ID: 22045706
[TBL] [Abstract][Full Text] [Related]
32. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
[TBL] [Abstract][Full Text] [Related]
33. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
[TBL] [Abstract][Full Text] [Related]
35. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
[TBL] [Abstract][Full Text] [Related]
36. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
[TBL] [Abstract][Full Text] [Related]
37. [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Hachemi M; Couturier O; Vervueren L; Fosse P; Lacœuille F; Urban T; Hureaux J
PLoS One; 2014; 9(2):e87629. PubMed ID: 24505298
[TBL] [Abstract][Full Text] [Related]
38. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
[TBL] [Abstract][Full Text] [Related]
39. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]